Synthesis of Methyl-1-(<i>tert</i>-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate via a Hofmann Rearrangement Utilizing Trichloroisocyanuric Acid as an Oxidant
作者:Zackary D. Crane、Paul J. Nichols、Tarek Sammakia、Peter J. Stengel
DOI:10.1021/jo101504e
日期:2011.1.7
A trichloroisocyanuric acid (TCCA) mediated Hofmann rearrangement was utilized to synthesize methyl-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate. A variety of functional groups are tolerated in this reaction including vinyl, cyclopropyl, pyridyl, aryl, benzyl, and nitro groups.
COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF
申请人:Korea Research Institute of Chemical Technology
公开号:US20210047277A1
公开(公告)日:2021-02-18
The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
[EN] COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS DESTINÉS À L'INHIBITION DE TNIK ET UTILISATIONS MÉDICALES ASSOCIÉES
申请人:KOREA RES INST CHEMICAL TECH
公开号:WO2019156439A1
公开(公告)日:2019-08-15
The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.